ELI LILLY AND COMPANY Available-for-sale Securities, Gross Unrealized Loss
ELI LILLY AND COMPANY (LLY) reported Available-for-sale Securities, Gross Unrealized Loss of $11.20 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-04-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2015-04-30
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized loss for the quarter ending 2015-03-31 was $11.20M, a 70.76% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized loss for the quarter ending 2014-12-31 was -$8.30M, a 1760.00% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized loss for the quarter ending 2014-09-30 was $11.70M.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized loss for the quarter ending 2014-06-30 was -$23.40M.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized loss for fiscal 2012 was $29.00M.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized loss for fiscal 2010 was $61.10M, a 39.92% decline from fiscal 2009.
- ELI LILLY AND COMPANY available-for-sale securities, gross unrealized loss for fiscal 2009 was $101.70M.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2015-03-31 | $11.20M 10-Q · filed 2015-04-30 | $2.90M derived: sum of 2 quarters · filed 2015-04-30 | $14.60M derived: sum of 3 quarters · filed 2015-04-30 | -$8.80M derived: sum of 4 quarters · filed 2015-04-30 |
| 2014-12-31 | -$8.30M derived: 10-Q 12 month − 10-Q 9 month · filed 2015-04-30 | $3.40M derived: sum of 2 quarters · filed 2015-04-30 | -$20.00M derived: sum of 3 quarters · filed 2015-04-30 | $18.30M 10-Q · filed 2015-04-30 |
| 2014-09-30 | $11.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | -$11.70M derived: sum of 2 quarters · filed 2014-10-29 | $26.60M 10-Q · filed 2014-10-29 | $27.10M derived: sum of 4 quarters · filed 2014-10-29 |
| 2014-06-30 | -$23.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-28 | $14.90M 10-Q · filed 2014-07-28 | $15.40M derived: sum of 3 quarters · filed 2014-10-29 | -$3.10M derived: sum of 4 quarters · filed 2014-10-29 |
| 2014-03-31 | $38.30M 10-Q · filed 2014-04-28 | $38.80M derived: sum of 2 quarters · filed 2014-10-29 | $20.30M derived: sum of 3 quarters · filed 2014-10-29 | |
| 2013-12-31 | $500.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2014-10-29 | -$18.00M derived: sum of 2 quarters · filed 2014-10-29 | $59.80M 10-Q · filed 2014-10-29 | |
| 2013-09-30 | -$18.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $59.30M 10-Q · filed 2013-10-30 | ||
| 2013-06-30 | $77.80M 10-Q · filed 2013-07-26 | |||
| 2012-12-31 | $29.00M 10-K · filed 2014-02-19 | |||
| 2010-12-31 | $61.10M 10-K · filed 2011-02-22 | |||
| 2010-09-30 | $61.20M 10-Q · filed 2010-10-29 | $142.50M derived: sum of 2 quarters · filed 2010-10-29 | ||
| 2010-06-30 | $81.30M 10-Q/A · filed 2010-08-02 | |||
| 2009-12-31 | $101.70M 10-Q · filed 2010-10-29 | $101.70M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |